Capital position remains strong with $5.4 billion in cash and investments and $579 million in excess capital at insurance subsidiaries.
Loss from operations was $230 million in Q2, a $298 million decrease year-over-year; adjusted EBITDA loss was $199 million, a $304 million decrease year-over-year.
Membership grew 28% year-over-year to over 2 million members, supported by strong retention and SEP additions.
Oscar Health reported Q2 2025 total revenue of $2.9 billion, a 29% year-over-year increase driven by higher membership.
SG&A expense ratio improved by 90 basis points year-over-year to 18.7%, driven by lower exchange fee rates and fixed cost leverage.
The medical loss ratio (MLR) increased 12 points year-over-year to 91.1%, impacted by a $316 million increase in risk adjustment payable due to higher market morbidity.
Da Vinci procedures increased 17% globally, with U.S. growth led by benign general surgery and international growth led by non-urology procedures.
GAAP net income was $658 million or $1.81 per share, up from $527 million or $1.46 per share last year.
Gross margin declined to 67.9% from 70% last year due to higher facilities costs, product mix, and tariffs.
Instrument and accessory revenue per procedure remained stable at approximately $1,800.
Pro forma operating margin was 39%, and pro forma earnings per share increased 23% to $2.19.
Second quarter revenue grew 21% to $2.44 billion, driven by strong procedure growth and capital placements.
SP procedures grew 88% year-over-year, and Ion procedures grew 52% to approximately 35,000.
System placements totaled 395, including 180 da Vinci 5 systems and 23 SP systems, with strong U.S. capital placements but macro challenges in Japan, China, and Europe.